3. Generally speaking, today's shrinking and counter-pumping is basically formed, so it is ok to hold shares in the directions mentioned above.(2) Second, the appreciation of RMB exchange rate is obvious today. Yesterday's trend made everyone dissatisfied, but yesterday's exchange rate performance was very firm. Some people say that the exchange rate strength has anything to do with investors?First, we must maintain the recognition of slow cattle, because only if you recognize that it is a slow bull market, can you insist on holding shares and take more positions at the low position.
It has a lot to do with it. If the exchange rate continues to depreciate unilaterally, it will make the whole market less confident in China's assets. If the exchange rate is stable, if it appreciates properly, it will attract some foreign capital to enter the market, and it will also be conducive to the appreciation of China's assets, and the stock market is no exception.The main reason is that yesterday's mood was too high, and the organization just had to wait until it calmed down before doing more. Of course, there will be another understanding, that is, the unexpected benefits will make some institutions empty, so some institutions need to continue to collect chips.(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.
(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide
Strategy guide
12-14
Strategy guide